| Literature DB >> 16483842 |
Edward J Sharples1, Christoph Thiemermann, Magdi M Yaqoob.
Abstract
Recombinant erythropoietin (EPO) was introduced into clinical practice after the identification of EPO as the major haemopoietic growth factor determining survival and maturation of erythroid precursors. Advances in our understanding of the novel sites of action of EPO in the vasculature, brain, heart and kidney have opened new avenues of therapeutic potential for EPO, and have led to an increased understanding of the biological roles of EPO and its mechanisms of cell protection.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16483842 DOI： 10.1016/j.coph.2006.01.003
Source DB: PubMed Journal: Curr Opin Pharmacol ISSN： 1471-4892 Impact factor: 5.547